FBRX Forte Biosciences, Inc.

NASDAQ
$76.83

Forte Biosciences, Inc. (FBRX) is expected to report earnings on November 11, 2026, before the market open. The consensus earnings estimate is a loss of $0.90 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.1% since its last earnings release on August 12, 2026.

Forte Biosciences Beat Consensus Estimates
Wednesday, August 12, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 9:00 AM ET
Earnings Whisper
-
vs ($0.90)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $76.81

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Forte Biosciences, Inc.

Forte Biosciences Inc. is a clinical stage, dermatology company. It engages in developing biotherapeutic, FB-401, for the treatment of inflammatory skin diseases which is in clinical stage. Forte Biosciences Inc., formerly known as Tocagen Inc., is based in Sherman Oaks, California.

Sector

Healthcare

Industry

Biotechnology